title: Enhancement of doxorubicin cytotoxicity by tanshinone IIA in HepG2 human hepatoma cells.
abstract: Chlorogenic acid (1), salvianolic acid B (2), and tanshinone IIA (3) are commonly used as chemoprotective agents for chemotherapy in cancer patients. The present study deals with the effect of these three compounds on cytotoxicity of doxorubicin in HepG2 cells. The results showed that 1 and 2 reduced the cytotoxicity of doxorubicin through scavenging ROS generated by doxorubicin in HepG2 cells. The findings suggest that 1 and 2 could enhance the expression of SOD and decrease that of NADPH oxidase, which resulted in the elimination of ROS. On the contrary, 3 enhanced the cytotoxicity of doxorubicin in HepG2 cells. Furthermore, drug interactions between doxorubicin and 3 produce synergistic effects in HepG2 cells.
authors.affiliation: School of Life Science, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
authors.forename: Shidong
authors.initials: S
authors.lastname: Kan
authors.affiliation: School of Life Science, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
authors.forename: Wan Man
authors.initials: WM
authors.lastname: Cheung
authors.affiliation: School of Life Science, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
authors.forename: Yanling
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: School of Life Science, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
authors.forename: Wing Shing
authors.initials: WS
authors.lastname: Ho
mesh_terms: D045784:Abietanes / Q000008:administration & dosage* / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D001572:Benzofurans / Q000008:administration & dosage; D053148:Caspase 3 / Q000378:metabolism; D002726:Chlorogenic Acid / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D056945:Hep G2 Cells / Q000187:drug effects; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D000074663:NADPH Oxidase 4; D019255:NADPH Oxidases / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D053630:Depsides
chemical_list: D045784:Abietanes; D000972:Antineoplastic Agents, Phytogenic; D000975:Antioxidants; D001572:Benzofurans; D053148:Caspase 3; D002726:Chlorogenic Acid; D004317:Doxorubicin; D007770:L-Lactate Dehydrogenase; D000074663:NADPH Oxidase 4; D019255:NADPH Oxidases; D017382:Reactive Oxygen Species; C021751:tanshinone; C076944:salvianolic acid B; D053630:Depsides; C498910:NOX4 protein, human